```
     FILE 'REGISTRY' ENTERED AT 14:21:47 ON 13 MAR 2009
L1              STRUCTURE UPLOADED
L2           15 S L1
L3          363 S L1 SSS FULL

     FILE 'HCAPLUS' ENTERED AT 14:23:00 ON 13 MAR 2009
L4            4 S L3
```

```
=> file registry
COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                     ENTRY    SESSION
FULL ESTIMATED COST                                   0.22       0.22

FILE 'REGISTRY' ENTERED AT 14:21:47 ON 13 MAR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   11 MAR 2009  HIGHEST RN 1119363-64-2
DICTIONARY FILE UPDATES:  11 MAR 2009  HIGHEST RN 1119363-64-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\STNEXP\Queries\10525197generic6.str
```





chain nodes :
7 19 20 21 22 23 24 27 28 29 30 31 32 33 34
ring nodes :
1 2 3 4 5 6 8 9 10 11 12 13 14 15 16 17 18
chain bonds :
2-7 5-32 7-8 12-19 13-23 13-30 14-22 14-29 15-21 15-27 17-19 17-20 18-24
18-31 27-28 32-33 33-34
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 8-9 8-12 9-10 10-11 11-12 13-14 13-18 14-15
15-16 16-17 17-18
exact/norm bonds :
5-32 8-9 8-12 9-10 10-11 11-12 12-19 13-14 13-18 13-30 14-15 14-29 15-16
16-17 17-18 17-19 18-31 32-33 33-34
exact bonds :
2-7 7-8 13-23 14-22 15-21 15-27 17-20 18-24 27-28
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

G1:O,S,C

G2:OH,H

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:CLASS
20:CLASS 21:CLASS
22:CLASS 23:CLASS 24:CLASS 27:CLASS 28:CLASS 29:CLASS 30:CLASS 31:CLASS
32:CLASS 33:CLASS
34:CLASS

L1 STRUCTURE UPLOADED

=> s l1
SAMPLE SEARCH INITIATED 14:22:12 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 28 TO ITERATE

100.0% PROCESSED 28 ITERATIONS 15 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 243 TO 877
PROJECTED ANSWERS: 68 TO 532

L2 15 SEA SSS SAM L1

=> d l2 scan

L2 15 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN L-Alanine, N-[3-[3-methyl-4-[[3-(1-methylethyl)-5-[(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl)oxy]-1H-pyrazol-4-yl]methyl]phenoxy]-1-oxopropyl]-, phenylmethyl ester
MF C41 H51 N3 O14

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):3

L2 15 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN β-D-Galactopyranoside, 4-[[4-[3-[(2-hydroxyethyl)amino]propoxy]-2-methylphenyl]methyl]-5-(1-methylethyl)-1H-pyrazol-3-yl
MF C25 H39 N3 O8

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 15 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN β-Alanine, N2-[3-[4-[[3-(β-D-glucopyranosyloxy)-5-(1-methylethyl)-1H-pyrazol-4-yl]methyl]-3-methylphenoxy]propyl]-L-α-asparaginyl-N-(phenylmethyl)-, phenylmethyl ester (9CI)
MF C44 H57 N5 O11

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 15 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzenebutanamide, N-[3-[bis(2-hydroxyethyl)amino]propyl]-4-[[3-(β-D-glucopyranosyloxy)-5-(1-methylethyl)-1H-pyrazol-4-yl]methyl]-
MF C30 H48 N4 O9

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> s l1 sss full

FULL SEARCH INITIATED 14:22:49 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 671 TO ITERATE

100.0% PROCESSED 671 ITERATIONS 363 ANSWERS
SEARCH TIME: 00.00.01

L3 363 SEA SSS FUL L1

=> file hcaplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 186.36 186.58

FILE 'HCAPLUS' ENTERED AT 14:23:00 ON 13 MAR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 13 Mar 2009 VOL 150 ISS 12
FILE LAST UPDATED: 12 Mar 2009 (20090312/ED)

HCAplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> s l3
L4 4 L3

=> d l4 1-4 ti abs bib hitstr

L4 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Preventive or remedy for diseases caused by hyperglycemia
AB It is intended to provide a medicinal composition containing as the active ingredient a selective SGLT1 inhibitor (for example, an SGLT1 inhibitor substantially showing no GLUT2 and/or GLUT5 inhibitory effect) which exerts a sugar absorption inhibitory effect over a wide range, also has a hypoglycemic effect caused by fructose intake in usual diet and thus can show an outstanding hypoglycemic effect and which is appropriate as a preventive or a remedy for diseases caused by hyperglycemia (for example, diabetes, impaired glucose tolerance, diabetic complications or obesity).
AN 2004:486406 HCAPLUS <<LOGINID::20090313>>
DN 141:47334
TI Preventive or remedy for diseases caused by hyperglycemia
IN Ito, Fumiaki; Shibazaki, Toshihide; Tomae, Masaki; Fushimi, Nobuhiko;

Isaji, Masayuki
PA Kissei Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 34 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004050122	A1	20040617	WO 2003-JP15503	20031204
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2507665	A1	20040617	CA 2003-2507665	20031204
AU 2003289156	A1	20040623	AU 2003-289156	20031204
EP 1568380	A1	20050831	EP 2003-777222	20031204
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1744916	A	20060308	CN 2003-80109504	20031204
US 20060035844	A1	20060216	US 2005-537495	20050603
IN 2005DN02385	A	20070105	IN 2005-DN2385	20050603
PRAI JP 2002-352201	A	20021204		
WO 2003-JP15503	W	20031204		

IT 705445-35-8P, 3-(β-D-Glucopyranosyloxy)-4-[[4-(2-guanidinoethoxy)-2-methylphenyl]methyl]-5-indolyl-1H-pyrazole
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(SGLT1 inhibitors as preventives or remedies for diseases caused by hyperglycemia)
RN 705445-35-8 HCAPLUS
CN Guanidine, [2-[4-[[3-(β-D-glucopyranosyloxy)-5-(1H-indol-1-yl)-1H-pyrazol-4-yl]methyl]-3-methylphenoxy]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN

TI Preparation of pyrazolyl glycoside derivatives as inhibitors of 1,5-anhydroglucitol/fructose/mannose transporters

GI



AB The title compds. [I; R = each (un)substituted C3-8 cycloalkyl, C6-10 aryl, C2-9 heterocycloalkyl, or C1-9 heteroaryl; R1 = H, each (un)substituted C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, C6-10 aryl, C2-9 heterocycloalkyl, or C1-9 heteroaryl; one of Q0 and T0 = α- or β-D-glucopyranosyloxy or -mannopyranosyloxy or β-D-deoxyglucopyranosyloxy- and the other = (CH2)nAr; wherein Ar = each (un)substituted C6-10 aryl or C1-9 heteroaryl; n = an integer of 0-2] or pharmacol. acceptable salts or prodrugs thereof are prepared Also disclosed are medicinal composition containing the compound I, medicinal use thereof, and intermediates in producing the same. These compds. exerts an excellent effect of inhibiting human 1,5-anhydroglucitol/fructose/mannose transporters and inhibit reabsorption or cellular uptake of glucose, fructose, and mannose in kidney or absorption of these saccharide small intestine and inhibit the increase in blood sugar. Therefore, they are useful as preventives, progress inhibitors or remedies for a disease caused by the over intake of at least one saccharide selected from among glucose, fructose, and mannose or a disease caused by hyperglycemia (diabetic complication, diabetes, or diabetic nephropathy). Thus, glycosidation of 1-isopropyl-5-(4-methoxyphenyl)-4-[(4-methoxyphenyl)methyl]-1,2-dihydro-3H-pyrazol-3-one by acetobromo-α-D-glucose in the presence of benzyltributylammonium bromide in a mixture of CH2Cl2 and 5 N aqueous NaOH at room temperature for 1.5 h followed by treatment of the product with NaOMe in MeOH gave 3-(β-D-glucopyranosyloxy)-1-isopropyl-5-(4-methoxyphenyl)-4-[(4-methoxyphenyl)methyl]-1H-pyrazole (II). II in vitro inhibited the uptake of [14C]methyl α-D-glucopyranoside in COS-7 cells transfected with human SMINT/PME18S-FL expression plasmid with IC50 of 92 nM.

AN 2004:311011 HCAPLUS <<LOGINID::20090313>>

DN 140:321649

TI Preparation of pyrazolyl glycoside derivatives as inhibitors of 1,5-anhydroglucitol/fructose/mannose transporters

IN Fujikura, Hideki; Kikuchi, Norihiko; Tazawa, Shigeki; Yamato, Tokuhisa; Isaji, Masayuki

PA Kissei Pharmaceutical Co., Ltd., Japan

SO PCT Int. Appl., 159 pp.

CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004031203	A1	20040415	WO 2003-JP12477	20030930
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2500873	A1	20040415	CA 2003-2500873	20030930
AU 2003272903	A1	20040423	AU 2003-272903	20030930
EP 1550668	A1	20050706	EP 2003-753967	20030930
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 20060128635	A1	20060615	US 2005-529895	20050919
PRAI JP 2002-293090	A	20021004		
JP 2002-330694	A	20021114		
JP 2002-378959	A	20021227		
WO 2003-JP12477	W	20030930		

OS MARPAT 140:321649
IT 678994-69-9P 678994-70-2P 678994-71-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrazolyl glycoside derivs. as inhibitors of 1,5-anhydroglucitol/fructose/mannose transporters and preventives, progress inhibitors or remedies for diabetic complication, diabetes, or diabetic nephropathy)
RN 678994-69-9 HCAPLUS
CN Acetamide, 2-[4-[[3-(β-D-glucopyranosyloxy)-5-(4-methoxyphenyl)-1-(1-methylethyl)-1H-pyrazol-4-yl]methyl]-3-methoxyphenoxy]- (CA INDEX NAME)

L4 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Preparation of 4-benzylpyrazolyl glucopyranosides and galactopyranoside derivatives as sodium-glucose cotransporter (SGLT1) inhibitors, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof
GI



I

AB Pyrazole derivs. represented by the general formula (I) [R1 = H, C1-6 alkyl, C2-6 alkenyl, hydroxy-C2-6 alkyl, C3-7 cycloalkyl, C3-7 cycloalkyl-C1-6 alkyl, each (un)substituted aryl or aryl-C1-6 alkyl; one of Q and T = Q1 or Q2 and the other = C1-6 alkyl, halo-C1-5 alkyl, C1-6 alkoxy-C1-6 alkyl, C3-7 cycloalkyl; R2 = H,halo, OH, C1-6 alkyl, C1-6 alkoxy,C1-6 alkylthio, halo-C1-6 alkyl, halo-C1-6 alkoxy, C1-6 alkoxy-C1-6 alkoxy, C3-7 cycloalkyl-C2-6 alkoxy, etc.; X = a single bond, O, S; Y = optionally hydroxy-substituted C1-6 alkylene or C2-6 alkenylene; Z = RB, CORC, SO2RC, CO(RD)RE, SO2NHRF, C(:NRG)N(RH)RI; wherein RC = each (un)substituted aryl, heteroaryl, or C1-6 alkyl; R4, RB, RD, RE, RF = H, each (un)substituted aryl, heteroaryl, or C1-6 alkyl; NR4RB or NRDRE together forms (un)substituted C2-6 cyclic amino; RG, RH, RI = H, (un)substituted C1-6 alkyl, etc.; R3, R5, R6 = H, halo, C1-6 alkyl, C1-6 alkoxy] or pharmacol. acceptable salts thereof are prepared These compds. have excellent human SGLT1 inhibitory activity and are useful as preventives or therapeutic agents for diseases attributable to hyperglycemia such as diabetes, impaired glucose tolerance, fasting blood sugar abnormality, complications of diabetes, obesity, hyperinsulinemia, hyperlipidemia, hypercholesteremia, hypertriglyceridemia, lipid metabolism disorder, atherosclerosis, hypertension, ischemic heart failure, edema, hyperuricemia, and gout and for diseases attributable to an increased blood galactose level such as galactosemia. For example, 3-(β-D-glucopyranosyloxy)-4-[[4-[3-[3-(2-hydroxy-1,1-dimethylethyl)ureido]propoxy]-2-methylphenyl]methyl]-5-isopropyl-1H-pyrazole in vitro inhibited the uptake of [14C]methyl α-D-glucopyranoside in CHO-K1 cells expressing human SGLT1 with IC50 of 19 nM. For another example, 3-(β-D-glucopyranosyloxy)-4-[[4-(2-guanidinoethoxy)-2-methylphenyl]methyl]-5-isopropyl-1H-pyrazole at 1 mg/kg p.o. lowered the serum glucose concentration from 303±63 (control) to 165±17 mg/dL after 1 h in rats with streptozotocin-induced diabetes.

AN 2004:182896 HCAPLUS <<LOGINID::20090313>>
DN 140:236000

TI Preparation of 4-benzylpyrazolyl glucopyranosides and galactopyranoside derivatives as sodium-glucose cotransporter (SGLT1) inhibitors, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof

IN Fushimi, Nobuhiko; Shimizu, Kazuo; Yonekubo, Shigeru; Teranishi, Hirotaka; Tomae, Masaki; Isaji, Masayuki
PA Kissei Pharmaceutical Co., Ltd., Japan

SO PCT Int. Appl., 270 pp.
CODEN: PIXXD2

DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004018491	A1	20040304	WO 2003-JP10551	20030821
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	JP 2004137245	A	20040513	JP 2002-324076	20021107
	CA 2496329	A1	20040304	CA 2003-2496329	20030821
	AU 2003262263	A1	20040311	AU 2003-262263	20030821
	EP 1548024	A1	20050629	EP 2003-792760	20030821
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003013694	A	20050705	BR 2003-13694	20030821
	CN 1688597	A	20051026	CN 2003-824499	20030821
	CN 100413878	C	20080827		
	ZA 2005001549	A	20060726	ZA 2005-1549	20030821
	NZ 538423	A	20070223	NZ 2003-538423	20030821
	US 20050272669	A1	20051208	US 2005-525197	20050222
	MX 2005002129	A	20050603	MX 2005-2129	20050223
	NO 2005001411	A	20050426	NO 2005-1411	20050317
	IN 2007DN07100	A	20071012	IN 2007-DN7100	20070913
PRAI	JP 2002-244381	A	20020823		
	JP 2002-324076	A	20021107		
	WO 2003-JP10551	W	20030821		
	IN 2005-DN666	A3	20050221		

OS MARPAT 140:236000

IT 666841-86-7P 666841-87-8P 666841-88-9P
666841-89-0P 666841-91-4P 666841-92-5P
666841-93-6P 666841-94-7P 666841-95-8P
666841-96-9P 666841-97-0P 666841-98-1P
666841-99-2P 666842-00-8P 666842-01-9P
666842-03-1P 666842-05-3P 666842-06-4P
666842-07-5P 666842-08-6P 666842-09-7P
666842-10-0P 666842-11-1P 666842-12-2P
666842-13-3P 666842-14-4P 666842-15-5P
666842-16-6P 666842-17-7P 666842-18-8P
666842-19-9P 666842-22-4P 666842-23-5P
666842-24-6P 666842-25-7P 666842-26-8P
666842-27-9P 666842-28-0P 666842-29-1P
666842-30-4P 666842-31-5P 666842-32-6P
666842-33-7P 666842-34-8P 666842-35-9P
666842-36-0P 666842-37-1P 666842-38-2P
666842-39-3P 666842-40-6P 666842-41-7P
666842-42-8P 666842-43-9P 666842-44-0P
666842-45-1P 666842-46-2P 666842-47-3P
666842-48-4P 666842-49-5P 666842-50-8P
666842-51-9P 666842-52-0P 666842-53-1P
666842-54-2P 666842-55-3P 666842-57-5P
666842-58-6P 666842-59-7P 666842-60-0P
666842-61-1P 666842-62-2P 666842-63-3P
666842-64-4P 666842-65-5P 666842-66-6P

666842-67-7P 666842-68-8P 666842-69-9P
666842-70-2P 666842-71-3P 666842-72-4P
666842-73-5P 666842-74-6P 666842-75-7P
666842-76-8P 666842-77-9P 666842-78-0P
666842-79-1P 666842-80-4P 666842-81-5P
666842-82-6P 666842-83-7P 666842-84-8P
666842-85-9P 666842-86-0P 666842-87-1P
666842-88-2P 666842-89-3P 666842-90-6P
666842-91-7P 666842-92-8P 666842-93-9P
666842-94-0P 666842-95-1P 666842-96-2P
666842-97-3P 666842-98-4P 666842-99-5P
666843-00-1P 666843-01-2P 666843-02-3P
666843-03-4P 666843-04-5P 666843-05-6P
666843-06-7P 666843-07-8P 666843-08-9P
666843-09-0P 666843-10-3P 666843-11-4P
666843-12-5P 666843-13-6P 666843-14-7P
666843-15-8P 666843-16-9P 666843-17-0P
666843-18-1P 666843-19-2P 666843-20-5P
666843-21-6P 666843-22-7P 666843-23-8P
666843-24-9P 666843-25-0P 666843-26-1P
666843-27-2P 666843-28-3P 666843-29-4P
666843-30-7P 666843-31-8P 666843-32-9P
666843-33-0P 666843-34-1P 666843-35-2P
666843-36-3P 666843-37-4P 666843-38-5P
666843-39-6P 666843-40-9P 666843-41-0P
666843-42-1P 666843-43-2P 666843-44-3P
666843-45-4P 666843-46-5P 666843-47-6P
666843-48-7P 666843-49-8P 666843-50-1P
666843-51-2P 666843-52-3P 666843-53-4P
666843-54-5P 666843-55-6P 666843-56-7P
666843-57-8P 666843-58-9P 666843-59-0P
666843-60-3P 666843-61-4P 666843-62-5P
666843-63-6P 666843-64-7P 666843-65-8P
666843-66-9P 666843-67-0P 666843-68-1P
666843-69-2P 666852-18-2P 666852-20-6P
666852-22-8P 666852-24-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzylpyrazolyl glucopyranosides and galactopyranosides as sodium-glucose cotransporter (SGLT1) inhibitors for prevention or treatment of diseases attributable to hyperglycemia or galactosemia)

RN 666841-86-7 HCAPLUS
CN β-D-Glucopyranoside, 4-[[4-(3-aminopropoxy)phenyl]methyl]-5-(1-methylethyl)-1H-pyrazol-3-yl, 2,3,4,6-tetraacetate (CA INDEX NAME)

L4 ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Preparation of pyrazolyl glucopyranoside and galactopyranoside derivatives inhibitors of human sodium-glucose cotransporter 1 (SGLT1), medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof
GI



I

AB Pyrazoles derivs. represented by the general formula (I) [R1 = H, C1-5 alkyl, C2-5 alkenyl, hydroxy-C2-5 alkyl, C3-7 cycloalkyl, C3-7 cycloalkyl-C1-6 alkyl (un)substituted aryl or aryl-C1-6 alkyl; one of Q and T = Q1, Q2 and the other = C1-5 alkyl, halo-C1-6 alkyl, C1-6 alkoxy-C1-6 alkyl, C3-7 cycloalkyl; R2 = H,halo, OH, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylthio, halo-C1-6 alkyl, halo-C1-6 alkoxy, C1-6 alkoxy-C1-6 alkoxy, C3-7 cycloalkyl-C2-6 alkoxy, etc.; X = a single bond, O, S; Y = a single bond, C1-6 alkylene, C2-6 alkenylene; Z = CO, SO2; R4, R5 = H, (un)substituted C1-6 alkyl; or NR4R5 together forms an (un)substituted C2-6 cyclic amino; R3, R6, R7 = H, halo, C1-6 alkyl, C1-6 alkoxy] or pharmacol. acceptable salts thereof or prodrug of either are prepared These compds. have excellent human SGLT1 inhibitory activity and are useful as preventives or therapeutic agents for (1) diseases attributable to hyperglycemia such as diabetes, impaired glucose tolerance, complications of diabetes, obesity, hyperinsulinemia, hyperlipidemia, hypercholesteremia, hypertriglycemia, lipid metabolism disorder, atherosclerosis, hypertension, ischemic heart failure, edema, hyperuricemia, or gout and (2) diseases attributable to high level of galactose, galactosemia. For example, 3-(β-D-glucopyranosyloxy)-4-[[4-[3-[2-hydroxy-1,1-bis(hydroxymethyl)ethylcarbamoyl]propyl]phenyl]methyl]-5-isopropyl-1H-pyrazole at 1 mg/kg p.o. lowered blood glucose in diabetic rats from 297±35 to 178±19 mg/dL in 1 h.

AN 2004:143172 HCAPLUS <<LOGINID::20090313>>
DN 140:199632

TI Preparation of pyrazolyl glucopyranoside and galactopyranoside derivatives inhibitors of human sodium-glucose cotransporter 1 (SGLT1), medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof

IN Teranishi, Hirotaka; Fushimi, Nobuhiko; Yonekubo, Shigeru; Shimizu, Kazuo; Shibazaki, Toshihide; Isaji, Masayuki
PA Kissei Pharmaceutical Co., Ltd., Japan

SO PCT Int. Appl., 215 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004014932	A1	20040219	WO 2003-JP10048	20030807

```
        W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
            CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
            GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS,
            LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG,
            PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR,
            TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
        RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
            KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
            FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
            BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
    CA 2494179           A1    20040219    CA 2003-2494179        20030807
    AU 2003254847        A1    20040225    AU 2003-254847         20030807
    EP 1544208           A1    20050622    EP 2003-784564         20030807
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
    BR 2003013290        A     20050705    BR 2003-13290          20030807
    CN 1688596           A     20051026    CN 2003-823929         20030807
    CN 100351263         C     20071128
    NZ 538117            A     20070126    NZ 2003-538117         20030807
    US 20060166899       A1    20060727    US 2005-523820         20050204
    US 7375087           B2    20080520
    MX 2005001549        A     20050505    MX 2005-1549           20050208
    NO 2005001209        A     20050415    NO 2005-1209           20050308
    HK 1082743           A1    20080502    HK 2006-102572         20060227
    US 20080312153       A1    20081218    US 2008-104890         20080417
PRAI JP 2002-232074      A     20020808
    JP 2002-321729       A     20021105
    WO 2003-JP10048      W     20030807
    US 2005-523820       A3    20050204
OS  MARPAT 140:199632
IT  661479-26-1P 661479-27-2P 661479-28-3P
    661479-29-4P 661479-30-7P 661479-31-8P
    661479-32-9P 661479-34-1P 661479-36-3P
    661479-37-4P 661479-38-5P 661479-39-6P
    661479-40-9P 661479-41-0P 661479-42-1P
    661479-44-3P 661479-45-4P 661479-46-5P
    661479-47-6P 661479-48-7P 661479-49-8P
    661479-50-1P 661479-51-2P 661479-52-3P
    661479-53-4P 661479-61-4P 661479-63-6P
    661479-65-8P 661479-67-0P 661479-73-8P
    661479-74-9P 661479-75-0P 661479-76-1P
    661479-77-2P 661479-78-3P 661479-79-4P
    661479-80-7P 661479-81-8P 661479-85-2P
    661479-86-3P 661479-87-4P 661479-88-5P
    661479-89-6P 661479-90-9P 661479-92-1P
    661479-93-2P 661479-94-3P 661479-95-4P
    661479-96-5P 661479-97-6P 661479-98-7P
    661479-99-8P 661480-03-1P 661480-04-2P
    661480-05-3P 661480-07-5P 661480-08-6P
    661480-09-7P 661480-10-0P 661480-12-2P
    661480-13-3P 661480-14-4P 661480-15-5P
    661480-16-6P 661480-17-7P 661480-18-8P
    661480-19-9P 661480-20-2P 661480-21-3P
    661480-22-4P 661480-24-6P 661480-25-7P
    661480-26-8P 661480-27-9P 661480-29-1P
    661480-32-6P 661480-35-9P 661480-37-1P
    661480-39-3P 661480-41-7P 661480-42-8P
    661480-43-9P 661480-44-0P 661480-46-2P
    661480-48-4P 661480-49-5P 661480-51-9P
    661480-53-1P 661480-54-2P 661480-55-3P
    661480-56-4P 661480-57-5P 661480-58-6P
```

661480-59-7P 661480-60-0P 661480-61-1P
661480-62-2P 661480-63-3P 661480-64-4P
661480-65-5P 661480-66-6P 661480-67-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrazolyl glucopyranoside and galactopyranoside derivs. inhibitors of human sodium-glucose cotransporter 1 (SGLT1) for preventives or therapeutics for diseases related to hyperglycemia or galactosemia)

RN 661479-26-1 HCAPLUS
CN Benzenebutanamide, N-(2-amino-2-oxoethyl)-4-[[3-(β-D-glucopyranosyloxy)-5-(1-methylethyl)-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)